COVID-19

NRx Pharmaceuticals and Hungarian Health Officials Agree on Pathway for ZYESAMI® and BriLife COVID-19 Vaccine Trials

12/14/2021

NRx and Hungary Agree on Regulatory Path for Emergency Use of ZYESAMI Hungary to Serve as First European Nation for the Registrational Phase 2b/3 BriLife COVID Vaccine Trial Excerpt from the Press Release: BUDAPEST, Hungary, Dec. 09, 2021 (GLOBE NEWSWIRE) — NRx Pharmaceuticals (NASDAQ: NRXP) today announced the conclusion of high-level meetings in Hungary that are expected to…

Read More

A New Class of Antiviral Therapy Could Treat COVID-19

12/14/2021

Excerpt from the Press Release: As the SARS-CoV-2 virus mutates, new variants emerge that can better evade immunity and spread more widely. This causes an ongoing race, in which scientists and pharmaceutical companies must continually test and adapt vaccines to keep up with the latest variant of the virus. This is similar to how the…

Read More

Ontario Brain Institute Releases Large Dementia Dataset to Further Accelerate Brain Research, Discovery, and Innovation through Brain-CODE, an Open Science Data Platform

12/10/2021

Excerpt from the Press Release: One of the more pressing calls-to-action in the aftermath of the COVID-19 pandemic has been the need to facilitate more accessible, effective, and seamless data sharing across the worldwide research community. The Ontario Brain Institute’s neuroinformatics platform, Brain-CODE, is achieving just that for global brain disorder research – recently launching their third clinical…

Read More

Immunome seeks OK to begin human testing of Covid-19 ‘cocktail,’ expects it to neutralize omicron

12/09/2021

Excerpt from the Press Release: A Chester County biopharmaceutical company has submitted an application with the Food and Drug Administration to begin human testing of its experimental “antibody cocktail” as a Covid-19 treatment. Exton-based Immunome said Wednesday it expects its antibody cocktail, known as IMM-BCP-01, can neutralize the recently discovered omicron variant. “Immunome designed its…

Read More

Pfizer testing its vaccine against new COVID-19 strain

12/03/2021

Excerpt from the Press Release: Pfizer said Friday that it can produce a COVID-19 vaccine for the new virus strain identified in South Africa in “approximately 100 days,” subject to government regulatory approval. The pharmaceutical firm said in a statement to CBS MoneyWatch that its researchers are now conducting tests to see if the company’s existing vaccine is effective…

Read More

A CDMO balancing act: Offering greater speed to market while adhering to regulatory requirements

12/02/2021

Mark W. Womack, CEO of Stelis Biopharma, shares his views on the speed and compliance balancing act to achieve quality during a contract manufacturing operation. Excerpt from the Press Release: The onset of the Covid-19 pandemic brought with it the exigent need for extraordinarily rapid development of treatments and vaccines to defend against a novel…

Read More

CN BIO and iiCON collaborate to validate novel Covid-19 research tools

12/02/2021

The Infection Innovation Consortium (iiCON) and organ-on-a-chip company (OOC) CN BIO have launched a research collaboration to validate the next generation of Covid-19 research tools. Excerpt from the Press Release: Led by the Liverpool School of Tropical Medicine (LSTM) iiCON is a £174 million programme that brings together industry, academia, and clinicals to accelerate the…

Read More

Plant-derived antiviral is effective in blocking highly infectious SARS-CoV-2 Delta variant, say scientists

12/01/2021

Date:November 19, 2021 Source:University of Nottingham Summary:A plant-based antiviral has been found to be just as effective at treating all variants of the virus SARS-CoV-2, even the highly infectious Delta variant. Excerpt from the Press Release: A plant-based antiviral, recently discovered by scientists at the University of Nottingham, has been found to be just as…

Read More

Canada gives full approval to J&J’s single-shot COVID-19 vaccine

11/30/2021

Excerpt from the Press Release: Nov 24 (Reuters) – Johnson & Johnson (JNJ.N) said on Wednesday Canada gave full approval to its single-shot COVID-19 vaccine for people aged 18 years and older, making it the first full approval for the vaccine globally. The vaccine was previously authorised by the country under an interim order. (https://refini.tv/30Zd5TR) Canada, which…

Read More